Mould A P, Komoriya A, Yamada K M, Humphries M J
Department of Biochemistry and Molecular Biology, University of Manchester Medical School, United Kingdom.
J Biol Chem. 1991 Feb 25;266(6):3579-85.
The alternatively spliced type III connecting segment (IIICS) region of fibronectin contains two distinct sites that support the adhesion of melanoma cells. These sites are contained within the synthetic peptides CS1 and CS5 (residues 1-25 and 90-109 of the IIICS, respectively). Recently, the cellular receptor for the CS1 site has been identified as the integrin heterodimer alpha 4 beta 1. In this report, we have investigated the role of the CS5 sequence in melanoma cell adhesion and the identity of its receptor. Adhesion to CS5, when presented to cells as an immobilized IgG conjugate, was blocked by antifunctional monoclonal antibodies directed against either the alpha 4 or beta 1 integrin subunits, but not by antibodies against other subunits, implying that alpha 4 beta 1 is also the receptor for CS5. In peptide inhibition experiments, CS5 was inhibitory for melanoma cell spreading on both CS5-IgG and CS1-IgG conjugates; conversely, CS1 inhibited spreading on both CS1-IgG and CS5-IgG. In both cases, peptide inhibition could be outcompeted by increasing the concentration of substrate-bound conjugate. These results suggest that CS1 and CS5 are recognized by the same or overlapping sites on alpha 4 beta 1. The minimal active sequence within CS5, the tetrapeptide Arg-Glu-Asp-Val (REDV), is somewhat related to the Arg-Gly-Asp-Ser (RGDS) sequence that represents a major active site in the central cell-binding domain (CCBD) of fibronectin. When RGDS peptide homologues were tested for their ability to inhibit spreading of melanoma cells on CS1- and CS5-IgG conjugates, GRGDS, GRGES, and REDV were found to be inhibitory, while GRDGS had no effect. In contrast, spreading on a fibronectin fragment containing the CCBD was inhibited by GRGDS only. GRGDS was also able to elute alpha 4 beta 1 specifically from a CS1 affinity column, confirming directly that alpha 4 beta 1-IIICS interactions are sensitive to peptides containing this recognition motif. Because the minimal active sequence within CS1 is the tripeptide Leu-Asp-Val (LDV; Komoriya et al., manuscript submitted for publication), these findings together define a new adhesive recognition sequence, X-Asp-Y, used by alpha 4 beta 1 for binding to fibronectin. The central aspartate residue in this tripeptide is almost always essential, but some flexibility in the amino acid residues at X (glycine, leucine, or glutamic acid) and Y (serine or valine) is tolerated. Potential models for the interaction of the IIICS region with alpha 4 beta 1 are discussed.
纤连蛋白的可变剪接III型连接段(IIICS)区域包含两个支持黑色素瘤细胞黏附的不同位点。这些位点存在于合成肽CS1和CS5中(分别为IIICS的第1 - 25位和90 - 109位残基)。最近,CS1位点的细胞受体已被鉴定为整合素异二聚体α4β1。在本报告中,我们研究了CS5序列在黑色素瘤细胞黏附中的作用及其受体的身份。当以固定化IgG偶联物形式呈现给细胞时,对CS5的黏附被针对α4或β1整合素亚基的抗功能单克隆抗体阻断,但不被针对其他亚基的抗体阻断,这意味着α4β1也是CS5的受体。在肽抑制实验中,CS5抑制黑色素瘤细胞在CS5 - IgG和CS1 - IgG偶联物上的铺展;相反,CS1抑制在CS1 - IgG和CS5 - IgG上的铺展。在这两种情况下,增加底物结合偶联物的浓度可竞争抑制肽的作用。这些结果表明CS1和CS5被α4β1上相同或重叠的位点识别。CS5内的最小活性序列,四肽精氨酸 - 谷氨酸 - 天冬氨酸 - 缬氨酸(REDV),与代表纤连蛋白中央细胞结合结构域(CCBD)中一个主要活性位点的精氨酸 - 甘氨酸 - 天冬氨酸 - 丝氨酸(RGDS)序列有些相关。当测试RGDS肽类似物抑制黑色素瘤细胞在CS1 - 和CS5 - IgG偶联物上铺展的能力时,发现GRGDS、GRGES和REDV具有抑制作用,而GRDGS没有效果。相比之下,仅GRGDS抑制在含有CCBD的纤连蛋白片段上的铺展。GRGDS还能够从CS1亲和柱上特异性洗脱α4β1,直接证实α4β1 - IIICS相互作用对含有该识别基序的肽敏感。因为CS1内的最小活性序列是三肽亮氨酸 - 天冬氨酸 - 缬氨酸(LDV;小森等,已提交发表的手稿),这些发现共同定义了一个新的黏附识别序列X - 天冬氨酸 - Y,α4β1用于与纤连蛋白结合。该三肽中的中央天冬氨酸残基几乎总是必不可少的,但X(甘氨酸、亮氨酸或谷氨酸)和Y(丝氨酸或缬氨酸)处的氨基酸残基有一定灵活性。讨论了IIICS区域与α4β1相互作用的潜在模型。